The 6-position of the uracil ring was activated for a lithiation reaction by condensing thymine with dimethylsulfamoyl chloride. X-ray crystallography was used to confirm the structure of the intermediate product 1- dimethylsulfamoylthymine, which was lithiated and subsequently treated with 2,6-difluorobenzaldehyde. The dimethylsulfamoyl group was removed by treatment with aq HCl and the alcohol was fluorinated with DAST. The fluoro-derivative was silylated and alkylated at the N1-position with bis(allyloxy)methane to give 1-allyloxymethyl-6-[(2,6-difluorophenyl)fluoromethyl]-5-methylpyrimidine-2,4(1H, 3H)-dione, which showed moderate activity against HIV-1. An attempt was also made to activate 5-methyl-2-(methylthio)pyrimidin-4(3H)-one with dimethylsulfamoyl chloride for a lithiation reaction. However, X-ray crystallography and subsequent reactions showed that the sulfamoylation had taken place on the oxygen at the 4-position.

Prompt lithiation of 1-dimethylsulfamoylthymine used for the synthesis of 1-allyloxymethyl-6-(a,2,6-trifluorobenzyl)thymine

LODDO, ROBERTA
2009

Abstract

The 6-position of the uracil ring was activated for a lithiation reaction by condensing thymine with dimethylsulfamoyl chloride. X-ray crystallography was used to confirm the structure of the intermediate product 1- dimethylsulfamoylthymine, which was lithiated and subsequently treated with 2,6-difluorobenzaldehyde. The dimethylsulfamoyl group was removed by treatment with aq HCl and the alcohol was fluorinated with DAST. The fluoro-derivative was silylated and alkylated at the N1-position with bis(allyloxy)methane to give 1-allyloxymethyl-6-[(2,6-difluorophenyl)fluoromethyl]-5-methylpyrimidine-2,4(1H, 3H)-dione, which showed moderate activity against HIV-1. An attempt was also made to activate 5-methyl-2-(methylthio)pyrimidin-4(3H)-one with dimethylsulfamoyl chloride for a lithiation reaction. However, X-ray crystallography and subsequent reactions showed that the sulfamoylation had taken place on the oxygen at the 4-position.
Antiviral agents; Heterocycles; HIV; Medicinal chemistry; Sulfonamides
File in questo prodotto:
File Dimensione Formato  
Pedersen 3589-3592 (2009).pdf

Solo gestori archivio

Tipologia: versione editoriale
Dimensione 151.94 kB
Formato Adobe PDF
151.94 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11584/17976
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact